TMO · Thermo Fisher Scientific Q2 FY2026 earnings call record财报电话会记录

“We also introduced the Thermo Scientific Orbitrap Excedion Mass Spectrometer, which enables scientists to reduce drug development risk and accelerate time to market for our pharma and biotech customers.”

“These examples provide a unique opportunity for us to engage with our customers, helping them solve current challenges, accelerate innovation, and move science forward.”

“Customer feedback has been very positive, and we're excited about the long-term impact these capabilities will have for our customers and for our company.”

“We're raising our revenue guidance to a new range of $47.4 billion-$48.1 billion, representing 6%-8% reported revenue growth over 2025.”

“We're also increasing our adjusted earnings per share guidance to be in the range of $24.93-$25.33, which now represents 9%-11% growth over 2025, and a $0.25 increase from our previous guidance at the midpoint.”

“The adjusted tax rate in Q2 was 11.6%, and average diluted shares were 371 million in Q2, 7 million lower year-over-year, driven by share repurchases, net of option dilution.”

“Year-to-date cash flow from operations was $3.3 billion, and free cash flow was $2.5 billion after investing $800 million of net capital expenditures.”

“In Q2, we also deployed $1.2 billion of capital to shareholders through $1 billion of share buybacks and approximately $175 million of dividends.”

“Q2 adjusted operating income for Life Sciences Solutions increased 13%, and adjusted operating margin was 37.0%, up 20 basis points versus the prior year quarter.”

“In this segment, Q2 adjusted operating income increased 30%, and adjusted operating margin was 23.0%, up 420 basis points versus the year ago quarter.”

“In aggregate for adjusted EPS, we are increasing the midpoint of our full year guidance by $0.25, comprised of the following: $0.30 from the strong performance in Q2, $0.05 from an increase to our revenue outlook for the second half of the year, partially offset by the impact of the divestiture of our microbiology business of $0.05, and a second half headwind from recent changes in FX rates of $0.05.”

“In terms of capital deployment, we're assuming $4 billion of share buybacks, with $3 billion completed in January and an additional $1 billion completed in the second quarter.”